BACKGROUND: Although statin lipid-lowering medications likely reduce perioperative ischemic complications, few data exist to describe statins' effects on risk for and outcomes of atrial fibrillation following noncardiac surgery. OBJECTIVE: To examine the association between treatment with statin medications and clinically significant postoperative atrial fibrillation (POAF) following major noncardiac surgery. METHODS: A retrospective cohort study of patients aged 18 years or older who underwent major noncardiac surgery between January 1, 2008, and December 31, 2008. Cases of clinically significant POAF were selected by using a combination of International Classification of Diseases-9 codes and clinical variables. We defined statin users as those whose pharmacy data included a charge for a statin drug on the day of surgery, the day after surgery, or both. RESULTS: Of 370,447 patients, 10,957 (3.0%) developed clinically significant POAF; overall, 79,871 (21.6%) received a perioperative statin. Patients receiving statins were generally older (68.8 vs 61.1 years; P <.001) and more likely to be receiving a beta-blocker (50.3% vs 21.6%; P < .001). Statin use was associated with a lower unadjusted rate of POAF (2.6% vs 3.0%; P < .001). After adjustment for patient risk factors and surgery type, odds for POAF remained significantly lower among statin-treated patients (adjusted odds ratio = 0.79; 95% confidence interval = 0.71-0.87; P < .001). Statin use was not associated with differences in cost, length of stay, or mortality among patients who developed POAF. CONCLUSION: Treatment with statin agents appears to be associated with a lower risk for clinically significant POAF following major noncardiac surgery.
BACKGROUND: Although statin lipid-lowering medications likely reduce perioperative ischemic complications, few data exist to describe statins' effects on risk for and outcomes of atrial fibrillation following noncardiac surgery. OBJECTIVE: To examine the association between treatment with statin medications and clinically significant postoperative atrial fibrillation (POAF) following major noncardiac surgery. METHODS: A retrospective cohort study of patients aged 18 years or older who underwent major noncardiac surgery between January 1, 2008, and December 31, 2008. Cases of clinically significant POAF were selected by using a combination of International Classification of Diseases-9 codes and clinical variables. We defined statin users as those whose pharmacy data included a charge for a statin drug on the day of surgery, the day after surgery, or both. RESULTS: Of 370,447 patients, 10,957 (3.0%) developed clinically significant POAF; overall, 79,871 (21.6%) received a perioperative statin. Patients receiving statins were generally older (68.8 vs 61.1 years; P <.001) and more likely to be receiving a beta-blocker (50.3% vs 21.6%; P < .001). Statin use was associated with a lower unadjusted rate of POAF (2.6% vs 3.0%; P < .001). After adjustment for patient risk factors and surgery type, odds for POAF remained significantly lower among statin-treated patients (adjusted odds ratio = 0.79; 95% confidence interval = 0.71-0.87; P < .001). Statin use was not associated with differences in cost, length of stay, or mortality among patients who developed POAF. CONCLUSION: Treatment with statin agents appears to be associated with a lower risk for clinically significant POAF following major noncardiac surgery.
Authors: George J Stukenborg; Douglas P Wagner; Frank E Harrell; M Norman Oliver; Steven W Heim; Amy L Price; Caroline Kim Han; Andrew M D Wolf; Alfred F Connors Journal: J Clin Epidemiol Date: 2006-11-13 Impact factor: 6.437
Authors: Paul M Ridker; Eleanor Danielson; Francisco A H Fonseca; Jacques Genest; Antonio M Gotto; John J P Kastelein; Wolfgang Koenig; Peter Libby; Alberto J Lorenzatti; Jean G MacFadyen; Børge G Nordestgaard; James Shepherd; James T Willerson; Robert J Glynn Journal: N Engl J Med Date: 2008-11-09 Impact factor: 91.245
Authors: P J Devereaux; Homer Yang; Salim Yusuf; Gordon Guyatt; Kate Leslie; Juan Carlos Villar; Denis Xavier; Susan Chrolavicius; Launi Greenspan; Janice Pogue; Prem Pais; Lisheng Liu; Shouchun Xu; German Málaga; Alvaro Avezum; Matthew Chan; Victor M Montori; Mike Jacka; Peter Choi Journal: Lancet Date: 2008-05-12 Impact factor: 79.321
Authors: Jari Halonen; Pirjo Halonen; Otso Järvinen; Panu Taskinen; Tommi Auvinen; Matti Tarkka; Mikko Hippeläinen; Tatu Juvonen; Juha Hartikainen; Tapio Hakala Journal: JAMA Date: 2007-04-11 Impact factor: 56.272
Authors: Prashant D Bhave; L Elizabeth Goldman; Eric Vittinghoff; Judith Maselli; Andrew Auerbach Journal: Am Heart J Date: 2012-10-26 Impact factor: 4.749
Authors: Elisabetta Patorno; Shirley V Wang; Sebastian Schneeweiss; Jun Liu; Brian T Bateman Journal: Pharmacoepidemiol Drug Saf Date: 2015-10-22 Impact factor: 2.890
Authors: John C Bonano; Ashley K Aratani; Tanmaya D Sambare; Stuart B Goodman; James I Huddleston; William J Maloney; David R Burk; Alistair J Aaronson; Andrea K Finlay; Derek F Amanatullah Journal: J Arthroplasty Date: 2021-05-25 Impact factor: 4.757